trans-3-hexenoyl raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
=== February === 12 February Using observations by ESA's CHEOPS telescope, scientists describe a unique configuration of a planetary system around the star LHS 1903, where the innermost and outermost planets are rocky, while the two middle planets have extended atmospheres. This provides support for the "inside-out" model of planet formation. A small polymerase ribozyme is described which can synthesize both its complementary strand and a copy of itself. This is interpreted as a substantial support for the "RNA world" hypothesis of the origin of life. Researchers at Iceberg Quantum publish a study describing the "Pinnacle Architecture", a fault-tolerant quantum computing design based on quantum low-density parity-check (qLDPC) codes. They show that a 2048-bit RSA integer could be factored with fewer than 100,000 physical qubits under standard hardware assumptions – an order-of-magnitude reduction compared to previous estimates. 24 February – Researchers in Switzerland report that centenarians show "youthful" blood profiles across 37 proteins, including markedly lower oxidative stress markers, suggesting that specific aging-related biological pathways are slowed in exceptional longevity. 26 February – Researchers in Australia report that serum bicarbonate levels in U.S. population data have risen by 7% since 1999, tracking increases in atmospheric carbon dioxide. Modelling suggests that, if current trends continue, average bicarbonate levels could approach the upper limit of today's accepted healthy range within 50 years.
== ADLM Annual Scientific Meeting == ADLM holds several scientific conferences each year, the largest of which is the ADLM Annual Scientific Meeting & Clinical Lab Expo. First held in 1949, this educational meeting and technology exposition is an event in the field of laboratory medicine, attracting an average of 20,000 participants.
== Automated solid phase polypeptide synthesis == Large scale custom peptide synthesis can be carried out either in a liquid solution or in solid phase. In general, peptides shorter than 8 amino acids are prepared more economically by solution chemistry. Peptides larger than 8 residues are generally assembled by solid phase chemistry. Solid phase peptide synthesis (SPPS) can be carried out either manually or in a fully automated fashion. Manual synthesis for short peptides is advantageous as it allows for more flexibility when scaling up and it permits troubleshooting of unexpected problems with more ease. For example, an operator can wash away piperidine during Fmoc deprotection, in the event of a power failure or instrument failure. Furthermore, thermodynamic mixing can be better controlled with a manual approach. On the other hand, large scale fully automated peptide synthesis instruments have the obvious advantage of unattended operation and extensive documentation of the synthesis run. Therefore, automated peptide synthesis is usually selected as the best choice for the synthesis of longer peptides in the mid-scale range.
Diazepam increases the central depressive effects of alcohol, other hypnotics/sedatives (e.g., barbiturates), other muscle relaxants, certain antidepressants, sedative antihistamines, opioids, and antipsychotics, as well as anticonvulsants such as phenobarbital, phenytoin, and carbamazepine. The euphoriant effects of opioids may be increased, leading to an increased risk of psychological dependence. Cimetidine, omeprazole, oxcarbazepine, ticlopidine, topiramate, ketoconazole, itraconazole, disulfiram, fluvoxamine, isoniazid, erythromycin, probenecid, propranolol, imipramine, ciprofloxacin, fluoxetine, and valproic acid prolong the action of diazepam by inhibiting its elimination. Alcohol in combination with diazepam may cause a synergistic enhancement of the hypotensive properties of benzodiazepines and alcohol. Oral contraceptives significantly decrease the elimination of desmethyldiazepam, a major metabolite of diazepam. Rifampin, phenytoin, carbamazepine, and phenobarbital increase the metabolism of diazepam, thus decreasing drug levels and effects. Dexamethasone and St John's wort also increase the metabolism of diazepam. Diazepam increases the serum levels of phenobarbital. Nefazodone can cause increased blood levels of benzodiazepines. Cisapride may enhance the absorption, and therefore the sedative activity, of diazepam. Small doses of theophylline may inhibit the action of diazepam. Diazepam may block the action of levodopa (used in the treatment of Parkinson's disease). Diazepam may alter digoxin serum concentrations.
The agency projected total energy investment of $3.4 trillion in 2026, with oil investment falling for a third consecutive year to below $500 billion, while natural gas investment rose to $330 billion—its highest in a decade—driven by new LNG projects in the United States and Qatar. Coal investment was projected to reach $180 billion, the highest since 2012. IEA Executive Director Fatih Birol described the situation as "the largest energy security crisis the world has ever faced", drawing a parallel with the oil shocks of the 1970s. Countries such as Australia and India have more sufficient reserves but face challenges with panic buying. Economies most reliant on the strait for energy imports are in Asia, with Europe also viewing the strait as vital for its energy security. The initial disruption of petroleum is expected to affect Asia the most, but Europe is likely to be hit hard in the medium-to-long term, and the UK is expected to be the worst-hit major economy. The British think tank The Food Policy Institute has warned of long-term increases in food prices due to disruption in fuel and fertiliser markets. The Strait of Hormuz is central to the global fertiliser trade. Over 30 per cent of global urea, which is widely used and produced from natural gas – is exported from Gulf countries through the Strait. Much of the cost of producing some foods, including corn and wheat, is in the cost of fertiliser, and this cost, along with rising energy costs, makes basic food production very expensive.
Sources: en.wikipedia.org
=== "Disc-at-risk" === The term "disc-at-risk" refers to an optic nerve head characterized by a small cup-to-disc ratio and a crowding of optic nerve fibers. This anatomical feature is a significant factor in the development of NAION. Individuals predisposed to this condition typically have smaller optic discs with minimal or no cupping. This anatomical configuration leads to a congestion of nerve fibers, which can contribute to the onset of NAION. This mechanism is somewhat similar to compartment syndrome, where increased pressure within a confined space impairs blood flow and tissue function.
== Structure == Disulfur difluoride has a chain structure F−S−S−F. The angle between the Fa−S−S and S−S−Fb planes is 87.9°, while the angles of Fa−S−S and S−S−Fb are equivalent, and are equal to 108.3°. Both S−F bonds are equivalent and their length is 163.5 pm, while the length of the S−S bond is 189 pm. This structure is referred to as gauche, and is similar to H2O2. There is a branched isomer of disulfur difluoride, thiothionyl fluoride, with the structure S=SF2.
These transfer proteins from the cytoplasm into the periplasm or into the environment around the cell. Many types of secretion systems are known and these structures are often essential for the virulence of pathogens, so are intensively studied.
== History of paper chromatography == The discovery of paper chromatography in 1943 by Martin and Synge provided, for the first time, the means of surveying constituents of plants and for their separation and identification. Erwin Chargaff credits in Weintraub's history of the man the 1944 article by Consden, Gordon and Martin. There was an explosion of activity in this field after 1945.
Sources: en.wikipedia.org
==== Fenestrated ==== Fenestrated capillaries have pores known as fenestrae (Latin for "windows") in the endothelial cells that are 60–80 nanometres (nm) in diameter. They are spanned by a diaphragm of radially oriented fibrils that allows small molecules and limited amounts of protein to diffuse. In the renal glomerulus the capillaries are wrapped in podocyte foot processes or pedicels, which have slit pores with a function analogous to the diaphragm of the capillaries. Both of these types of blood vessels have continuous basal laminae and are primarily located in the endocrine glands, intestines, pancreas, and the glomeruli of the kidney.
Complexes of macromolecules occur ubiquitously in nature, where they are involved in the construction of viruses and all living cells. In addition, they play fundamental roles in all basic life processes (protein translation, cell division, vesicle trafficking, intra- and inter-cellular exchange of material between compartments, etc.). In each of these roles, complex mixtures of become organized in specific structural and spatial ways. While the individual macromolecules are held together by a combination of covalent bonds and intramolecular non-covalent forces (i.e., associations between parts within each molecule, via charge-charge interactions, van der Waals forces, and dipole–dipole interactions such as hydrogen bonds), by definition MAs themselves are held together solely via the noncovalent forces, except now exerted between molecules (i.e., intermolecular interactions).
=== Brand names === Naltrexone is or has been sold under a variety of brand names, including Adepend, Antaxone, Celupan, Depade, Destoxican, Nalorex, Narcoral, Nemexin, Nodict, Revia, Trexan, Vivitrex, and Vivitrol. It is also marketed in combination with bupropion (naltrexone/bupropion) as Contrave, and was marketed with morphine (morphine/naltrexone) as Embeda. A combination of naltrexone with buprenorphine (buprenorphine/naltrexone) has been developed, but has not been marketed.
In July 2020, the European Union granted a conditional marketing authorization for remdesivir with an indication for the treatment of COVID‑19 in adults and adolescents (aged twelve years and older with body weight at least 40 kilograms [88 lb]) with pneumonia requiring supplemental oxygen. In August 2022, the European Union granted a full marketing authorization for remdesivir.
=== Tribofilm formation mechanism === Various mechanisms have been proposed for how ZDDP forms protective tribofilms on solid surfaces. In-situ atomic-force microscopy (AFM) experiments show that the growth of ZDDP tribofilms increases exponentially with both the applied pressure and temperature, consistent with a stress-promoted thermal activation reaction rate model. Subsequently, experiments with negligible solid-solid contact demonstrated that film formation rate depends on the applied shear stress.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.